Journal of Psychopharmacology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
0269881106067765v1
20/6/863    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shastri, M.
Right arrow Articles by Sabaratnam, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shastri, M.
Right arrow Articles by Sabaratnam, M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
This version was published on November 1, 2006
Journal of Psychopharmacology, Vol. 20, No. 6, 863-867 (2006)
DOI: 10.1177/0269881106067765

Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series

Manan Shastri

Staff Grade Psychiatrist, Ealing Community Team for People with Intellectual Disabilities, Hanwell, London, UK

Lakshmiramana Alla

Staff Grade Psychiatrist, Three Bridges Regional Secure Unit, Southall, London, UK

Manga Sabaratnam

Consultant Psychiatrist, Ealing Community Team for People with Intellectual Disabilities, Hanwell, London, UK

People with intellectual disabilities may be at greater risk of developing movement disorders as a consequence of their underlying neurological damage, especially when they are treated with typical antipsychotic agents. Aripiprazole is a novel antipsychotic quinolone derivative that has been approved for the treatment of schizophrenia in adults. However, there are few reports on the use of aripiprazole in people with intellectual disabilities. Herein, we report on the use of aripiprazole in five individuals with intellectual disabilities and psychotic illness (four cases) or challenging behaviour (one case). Four of the five patients had an additional diagnosis of schizophrenia and one had autism spectrum disorder and challenging behaviour. Issues related to the usefulness of aripiprazole in the management of schizophrenia and challenging behaviour in people with intellectual disabilities are also discussed. Aripiprazole was well tolerated and effective in each of the cases and appears to be a safe and efficacious alternative in the management of patients with both intellectual disabilities and schizophrenia. It can also be a useful treatment option in the management of challenging behaviour, especially when it is used as a part of a biopsychosocial approach.

Key Words: aripiprazole • schizophrenia • intellectual disability • psychotic disorders • behavioural disorders • challenging behaviour


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 The Annals of PharmacotherapyHome page
J. M Stachnik and C. Nunn-Thompson
Use of Atypical Antipsychotics in the Treatment of Autistic Disorder
Ann. Pharmacother., April 1, 2007; 41(4): 626 - 634.
[Abstract] [Full Text] [PDF]